Matinas BioPharma Holdings, Inc. MTNB
Biotechnology: Pharmaceutical Preparations · IPO 2017 · data as of November 13, 2026
Matinas BioPharma Holdings, Inc. (MTNB) is a healthcare company listed in the US with a market value of about $881568.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -98%.
About Matinas BioPharma
Matinas BioPharma is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2017. Revenue went from $194494 in 2015 to $1M in 2023, growth of about 24.1% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 26% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $1M | $3M | $33000 | $158333 | $89812 | $119750 | $149687 | $0 |
| Net income | -$10M | -$24M | -$23M | -$21M | -$23M | -$22M | -$17M | -$14M | -$15M | -$8M |
| Free cash flow | — | — | -$15M | -$20M | -$15M | -$17M | -$14M | -$11M | -$12M | -$6M |
| EPS (diluted) | $-2.00 | $-4.98 | $-5.28 | $-5.00 | $-5.50 | $-6.00 | $-6.50 | $-7.50 | $-18.00 | $-10.50 |
| Net margin | — | — | -2093.2% | -658.6% | -70554.5% | -14177.0% | -19343.4% | -11760.4% | -10345.9% | — |
| ROIC | -89.0% | -234.2% | -82.4% | -47.7% | -34.2% | -28.4% | -40.2% | -51.6% | -120.1% | -89.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Matinas BioPharma pay a dividend?
Not currently.
Is Matinas BioPharma a good stock to buy?
We do not give buy or sell advice. Matinas BioPharma scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.